95 related articles for article (PubMed ID: 33396968)
1. Biophysical characterization of small molecule antiviral-loaded nanolipogels for HIV-1 chemoprophylaxis and topical mucosal application.
Ramanathan R; Jiang Y; Read B; Golan-Paz S; Woodrow KA
Acta Biomater; 2016 May; 36():122-31. PubMed ID: 26947382
[TBL] [Abstract][Full Text] [Related]
2. Development of tenofovir monobenzyl ester phosphonoamidate prodrugs with improved anti-hepatitis B virus activity and intrahepatic tenofovir enrichment.
Sun X; Song L; Lin L; Ding A; Wang C; Ma X; Zhou S; Cai J; Tang H
Bioorg Med Chem; 2024 Feb; 99():117607. PubMed ID: 38246114
[TBL] [Abstract][Full Text] [Related]
3. Antiviral supramolecular polymeric hydrogels by self-assembly of tenofovir-bearing peptide amphiphiles.
Monroe MK; Wang H; Anderson CF; Qin M; Thio CL; Flexner C; Cui H
Biomater Sci; 2023 Jan; 11(2):489-498. PubMed ID: 36449365
[TBL] [Abstract][Full Text] [Related]
4. ω-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties.
Pribut N; D'Erasmo M; Dasari M; Giesler KE; Iskandar S; Sharma SK; Bartsch PW; Raghuram A; Bushnev A; Hwang SS; Burton SL; Derdeyn CA; Basson AE; Liotta DC; Miller EJ
J Med Chem; 2021 Sep; 64(17):12917-12937. PubMed ID: 34459598
[TBL] [Abstract][Full Text] [Related]
5. Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.
Owen A; Rannard S
Adv Drug Deliv Rev; 2016 Aug; 103():144-156. PubMed ID: 26916628
[TBL] [Abstract][Full Text] [Related]
6. Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis.
Ilomuanya MO; Hameedat AT; Akang EN; Ekama SO; Silva BO; Akanmu AS
Futur J Pharm Sci; 2020; 6(1):81. PubMed ID: 33241057
[TBL] [Abstract][Full Text] [Related]
7. Current drugs for HIV-1: from challenges to potential in HIV/AIDS.
Peng Y; Zong Y; Wang D; Chen J; Chen ZS; Peng F; Liu Z
Front Pharmacol; 2023; 14():1294966. PubMed ID: 37954841
[TBL] [Abstract][Full Text] [Related]
8. A review of existing strategies for designing long-acting parenteral formulations: Focus on underlying mechanisms, and future perspectives.
Shi Y; Lu A; Wang X; Belhadj Z; Wang J; Zhang Q
Acta Pharm Sin B; 2021 Aug; 11(8):2396-2415. PubMed ID: 34522592
[TBL] [Abstract][Full Text] [Related]
9. Electrochemical Detection of Tenofovir through Quenching of Chloride Ion-Mediated Gold Electrodissolution.
Brunet Cabré M; Okumu F; McKelvey K
Langmuir; 2024 Feb; 40(8):4314-4320. PubMed ID: 38353065
[TBL] [Abstract][Full Text] [Related]
10. What Clinicians Need to Know About the Development of Long-Acting Formulations.
Flexner C; Thomas DL; Clayden P; Swindells S
Clin Infect Dis; 2022 Nov; 75(Suppl 4):S487-S489. PubMed ID: 36410382
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis and Actual Applications of the Polymers Containing Acidic P-OH Fragments: Part 1. Polyphosphodiesters.
Nifant'ev IE; Ivchenko PV
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499185
[TBL] [Abstract][Full Text] [Related]
12. An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate.
Baum MM; Butkyavichene I; Churchman SA; Lopez G; Miller CS; Smith TJ; Moss JA
Int J Pharm; 2015 Nov; 495(1):579-587. PubMed ID: 26386138
[TBL] [Abstract][Full Text] [Related]
13. Computational Modeling of Antiviral Drug Diffusion from Poly(lactic- co-glycolic-acid) Fibers and Multicompartment Pharmacokinetics for Application to the Female Reproductive Tract.
Halwes ME; Tyo KM; Steinbach-Rankins JM; Frieboes HB
Mol Pharm; 2018 Apr; 15(4):1534-1547. PubMed ID: 29481088
[TBL] [Abstract][Full Text] [Related]
14. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
Parikh UM; Mellors JW
Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
Fung HB; Stone EA; Piacenti FJ
Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284
[TBL] [Abstract][Full Text] [Related]
16. A New Approach to Developing Long-Acting Injectable Formulations of Anti-HIV Drugs: Poly(Ethylene Phosphoric Acid) Block Copolymers Increase the Efficiency of Tenofovir against HIV-1 in MT-4 Cells.
Nifant'ev I; Siniavin A; Karamov E; Kosarev M; Kovalchuk S; Turgiev A; Nametkin S; Bagrov V; Tavtorkin A; Ivchenko P
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396968
[TBL] [Abstract][Full Text] [Related]
17. Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.
Taneva E; Crooker K; Park SH; Su JT; Ott A; Cheshenko N; Szleifer I; Kiser PF; Frank B; Mesquita PM; Herold BC
Antimicrob Agents Chemother; 2015 Dec; 60(3):1667-75. PubMed ID: 26711762
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
